Whitfield Advises SK Capital Partners on Acquisition of Apotex
Overview
The source reports an SK Capital-affiliated fund’s agreement to acquire Apotex Pharmaceutical Holdings.
Target profile
Apotex is described as a Canadian pharmaceutical business supplying generic medicines across therapeutic areas and international markets.
Closing conditions
The announcement states that regulatory conditions remained to be satisfied and does not disclose a purchase price.
Advisory team
Matthew Arenson, Peter Stach and Jeremy Liss are identified as corporate leads, with specialists covering financing, tax, benefits, employment, real estate, environmental issues, technology and healthcare regulation. The record describes an announced agreement, rather than independently confirming completion or current ownership.
Sources & Further Reading
Related Pages
Whitfield Advises AEVEX on Acquisition of BlackSea TechnologiesWhitfield Advises Thrive Holdings on $2 Billion FundraiseWhitfield Represents Trinity Hunt Partners on Investment in Fisher Management PartnersBrusselsChicagoDallas
View More (17)
MiamiWashington, D.C.Technology & IP TransactionsAntitrust & CompetitionDebt FinanceDerivativesEmployee BenefitsEmployment & LaborEnvironmentalExecutive CompensationHealthcare & Life Sciences TransactionsInsurance Transactions & RegulatoryInternational Trade & National SecurityMergers & AcquisitionsPrivate EquityReal EstateTax
